Completed PHASE1 INTERVENTIONAL 1-arm NCT03244280

A Study of the Systemic Absorption of MOB015B

A Study of the Systemic Absorption of Once Daily MOB015B When Applied for 28 Days in Subjects With Moderate to Severe Onychomycosis of the Toenails.

Sponsor: Moberg Pharma AB

Conditions Onychomycosis

Interventions MOB015B

Updated 7 times since 2017 Last updated: May 2, 2018 Started: Dec 16, 2017 Primary completion: Apr 23, 2018 Completion: Apr 23, 2018

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT03244280, this PHASE1 trial focuses on Onychomycosis and remains completed. Sponsored by Moberg Pharma AB, it has been updated 7 times since 2017, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Status Flow

Change History

7 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE1
Jul 2024 — Sep 2024 [monthly]

Completed PHASE1
Jan 2021 — Jul 2024 [monthly]

Completed PHASE1
Jun 2018 — Jan 2021 [monthly]

Completed PHASE1

Status: Active Not Recruiting → Completed
May 2018 — Jun 2018 [monthly]

Active Not Recruiting PHASE1

Status: Recruiting → Active Not Recruiting

▶ Show 2 earlier versions

Feb 2018 — May 2018 [monthly]

Recruiting PHASE1

Status: Not Yet Recruiting → Recruiting
Aug 2017 — Feb 2018 [monthly]

Not Yet Recruiting PHASE1

First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Moberg Pharma AB

Data source: Moberg Pharma AB

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Austin, United States